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Patients with MT of any age, on ICT for at least three years,
were sequentially enrolled at eight Italian Thalassemia Care
Centers. HRQoL was measured in >14 year-old, patients, who
completed 2 generic instruments, EQ-5D and Short Form-36 (SF-
36). RESULTS: Results refer to 121 patients, with median age =
29.8 (14.1–48.5), 49.6% male. At enrolment 87.6% of patients
had at least one thalassemia related complication, 48.3% were
treated with Deferoxamine, 32.5% treated with Deferiprone,
19.2% were treated with both; 14.0% changed treatment
regimen at least once during the observational period (11.6
median months). EQ-5D proﬁle patients reported moderate
problems with “mobility” (9.1%), “self care” (0.8%), “usual
activities” (23.5%), moderate or severe “pain/discomfort”
(60.5%) and “anxiety/depression” (39.5%). The EQ-Visual
Analogue Scale had a mean = 73.0 (median = 75.0, from 30 to
100). Similar trends were observed with the SF-36 ones: in par-
ticular the mean + SD Physical Component Summary score was
47.7 + 8.4; the mean + SD Mental Component Summary score
was 45.1 + 8.8. CONCLUSIONS: Thalassemic patients have
impaired levels HRQoL: both physical and mental components
seem to be compromised from the disease or ICT and related
consequences. Therapies improving patients’ satisfaction with
and compliance to ICT may have positive consequences not only
on clinical effectiveness but also on overall patient’s wellbeing.
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OBJECTIVES: Patients with thalassemia, sickle cell disease
(SCD), and myelodysplastic syndromes (MDS) require infusion
iron chelation therapy (ICT) involving 8–12 hour infusions, 5
days per week, potentially limiting quality of life (QoL) and
inhibiting adherence in patients already limited by their condi-
tion. Thus, satisfaction with ICT is an important treatment
outcome. To date, there is no well-established measure to quan-
tify patient satisfaction with ICT. The aim of this study is to
describe the development and scoring of a treatment satisfaction
instrument for patients taking ICT. METHODS: Based on a lit-
erature review, and patient and clinician interviews, a 28-item
instrument was developed as funded by Novartis. This included
an assessment of: satisfaction with prior experience with ICT;
satisfaction with ICT characteristics; adherence to treatment;
preferences; and behavioural intentions. U.S. and U.K. patients
with thalassemia, SCD, or MDS (n = 110) currently taking ICT
completed the satisfaction instrument. The scoring of the instru-
ment and the assessment of its reliability and validity was per-
formed on the 19 satisfaction items. The 9 items related to past
experience, intentions and preferences were scored separately.
RESULTS: The Principal Component Analysis using a varimax
rotation revealed a four dimensional structure that explained
63% of the total variance. The factors of the Satisfaction with
ICT instrument were labelled: Perceived Effectiveness of ICT (6
items); Burden of ICT (5 items); Acceptance of ICT (5 items);
and Side-effects of ICT (3 items). Internal consistency reliability
for all subscales was good, with alpha coefﬁcients ranging
between 0.80 for Acceptance of ICT to 0.86 for Perceived Effec-
tiveness. CONCLUSIONS: Preliminary analyses suggest that the
Satisfaction with ICT instrument is reliable. Further validation
of the instrument is required to assess its test-retest reliability,
construct validity and responsiveness. The instrument could be
used in routine clinical practice or in clinical trials to measure
satisfaction with ICT.
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OBJECTIVE: Treatment for hemophilia patients with inhibitors
is costly and challenging for its complexity, without clear agree-
ment on drug selection or optimal dosing regimen for the ﬁrst-
line management of bleeding episodes. This study sought to
identify treatment attributes that are important to hematologists
in the United States. METHODS: A conjoint analysis was con-
ducted to elicit preferences using a discrete choice experiment.
Twelve attributes were assessed: risk of human viral infections,
possibility that the titer of the inhibitor may rise, reduction 
in the likelihood of dose-related thromboembolic events, the
number of infusions required to stop hemorrhage, infusion
preparation time, infusion time, infusion volume, time required
to stop bleeding, time required to alleviate pain, prophylaxis use,
ability to undergo major surgery, and cost of medications. Thirty
hematologists completed questionnaires involving twelve choice
tasks with trade-offs between three scenarios (most likely to use,
no preference, and least likely to use). Data were analyzed using
a multinomial logit model to obtain relative importance of each
attribute. RESULTS: Responding hematologists (with an average
of 13 years of experience treating hemophilia patients with
inhibitors) treat on average a total of 28 patients including four
inhibitor patients per month. “Time required to stop bleeding”
was the most important factor affecting treatment decisions (rel-
ative importance (RI) = 16.3%). Physicians also preferred treat-
ment products that possessed quick pain relief (RI = 12.9%), no
possibility that the titer of inhibitor may rise (RI = 12.8%), fewer
number of infusions required to stop a hemorrhage (RI =
12.7%), and absence of risk of human viral infection (RI =
10.8%). CONCLUSIONS: The study revealed the most impor-
tant attributes of treatment for hemophilia patients with
inhibitors from the physician perspective. Future studies should
compare physician preferences with those of hemophilia patients
with inhibitors.
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Patients with β-Thalassemia Major (MT) require life-long blood
transfusions, which often cause iron overload that, if left
untreated, may increase patients’ morbidity and mortality. Iron
Chelation Treatment (ICT), is based on 8–12 hour infusions of
Deferoxamine for 5–7 days/week and/or Deferiprone orally
administered. ICT aims to reduce iron overload but low satis-
faction and low compliance, lead to potentially negative conse-
quences on treatment effectiveness. OBJECTIVES: To investigate
ICT satisfaction in MT patients and explore its relationship with
their thinking about stopping medication. METHODS: The
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Italian-THAlassemia-Cosy-&-Outcomes-Assessment (ITHACA)
was a naturalistic multicentre study conducted to evaluate costs,
quality of life, compliance and treatment satisfaction in MT
patients undergoing ICT. In total 126 MT patients >12 years old
completed a 28-item satisfaction instrument consisting of 4
domains (perceived effectiveness, burden, side effects, accep-
tance. Response continuum ranged from 1 (very dissatisﬁed) to
5 (very satisﬁed). RESULTS: The median age was 29.4 years
(12.3–48.5), with an equal proportion of males and females. At
enrolement, 48.0% were treated with Deferoxamine, 33.6%
with Deferiprone and 18.4% with combination treatment.
86.5% of patients had at least one MT-related complication and
13.5% changed treatment regimens at least once during the
observational period (11.6 median months). Mean satisfaction
scores for “acceptance”, “side effects”, “burden” and “perceived
effectiveness” were 3.37, 3.57, 3.87 and 4.29 respectively. Simple
linear regression analysis showed that satisfaction with “accep-
tance” (R2 = 11%), “burden” (R2 = 13%) and “side effects”
(R2 = 12.3%) are signiﬁcantly and positively associated with the
adherence item “never thinking about stopping medication” 
(p < 0.0001 in both cases). CONCLUSIONS: The level of satis-
faction with “burden”, “acceptance” and “side effects” in MT
patients undergoing ICT can help to predict patient adherence.
Strategies able to improve satisfaction with ICT are expected to
increase patients’ adherence, with potential signiﬁcant conse-
quences on treatment effectiveness.
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OBJECTIVES: New anticoagulant drugs, alternative to vitamin
K antagonist (VKA) are currently under clinical evaluation.
Patients’ preferences should be considered in the development of
new therapeutic strategies. Objective of this study was to elicit
patients’ preferences on different treatment options. METHODS:
A discrete-choice-exercise (2 different scenarios in 9 pair-wise
comparisons) was applied to consecutive patients of all ages on
stable OAT or during their OAT starting-visit. The following
attributes were considered to be important after interviewing 20
patients and 6 physicians: route and number of administrations,
monitoring frequency, minor bleedings (few vs. no), treatment
out-of-pocket payment (€0 vs. €15 vs. €75/month), drugs/food
interactions and dose-adjustment (required vs. not-required). The
Possible relationship between sociodemographic and/or clinical
characteristics of the respondents and their preferences were eval-
uated. RESULTS: The questionnaire was completed by 237
patients (55%male; mean-age = 63/ds = 14; 41%on-stable-OAT).
A signiﬁcant monetary discrimination was reached for all attrib-
utes, except “interactions” and “dose adjustment”. The condi-
tional-probit-model demonstrated that patients are willing-to-pay
(WTP) per month: €79 for once-daily administration-tablets vs
one subcutaneous weekly-injection; €41 for once-daily adminis-
tration-tablets vs. twice-daily administration-tablets; €21 for
once-monthly vs. twice-monthly; €18 for each 6 month vs. once-
monthly visits; €23 for a drug without bleeding-risk. The model
showed important differences between stable and starting OAT
patients: the WTP for less frequent monitoring and no interac-
tions is greater for patients in stable-OAT; the WTP to avoid bleed-
ings is greater for starting patients. Also the employment status
matters: employed patients are more willing to pay for a treat-
ment with less frequent monitoring. CONCLUSIONS: To our
knowledge, this study is the ﬁrst to elicit preferences from patients
in OAT. The importance of this study is the achievement of
patient’s preferences in a simply and well accepted method to
allow planning optimal health care.
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OBJECTIVES: To estimate impact of dutasteride reimbursement
on budget from the perspective of National Health Fund (NHF)
in Poland. METHODS: Decision-analytic model was developed
to assess budget impact of dutasteride. Costs and resource use
are from published literature and NHF catalogue of procedures.
Costs of drugs, surgical intervention and prostate cancer treat-
ment were taken into account. Clinical data, including compli-
cations and prostate cancer rates, were obtained from the clinical
effectiveness analyses of dutasteride. Budget impact analysis was
performed in four different scenarios with regard to reimburse-
ment reference price and rates (Scenario 1: 50% reimbursement
rate, reference price = reference price for Penester; Scenario 2:
50% reimbursement rate, reference price = Avodart price; Sce-
nario 3: 70% reimbursement rate, reference price = reference
price for Penester; Scenario 4: 70% reimbursement rate, refer-
ence price = Avodart price). RESULTS: In case of Avodart (dutas-
teride) reimbursement, NHF would save: 65,888–562,612 PLN
in year 1, 197,664–1,687,836 PLN in year 2, 300,477–
2,625,523 PLN in year 3 and 376,229–3,212,590 PLN in year
4 and later, depending on assumed reimbursement reference price
and rate. CONCLUSIONS: Reimbursement of dutasteride
would result is savings from the perspective of the National
Health Fund in Poland.
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OBJECTIVE: The choice is between two types of hormones used
for follicle stimulation in IVF treatment—recom-binant FSH
(rFSH) and the urine-derived menotrophin. A literature review
by NICE in the UK carried out in 2004 documented that the two
types of hormones were equally effective and safe consequently
it was recommended to use the cheaper menotrophin. Based on
ﬁndings by the European and Israeli Study Group (EIGS), the
objective was to analyse the health economic consequences of
this choice between the two types of hormone in IVF treatment
in Denmark. METHODS: Based on the EISG study a prospec-
tive cost-effectiveness analysis, which compared menotrophin
(Menopur®) and rFSH (Gonal-F®), was carried out. The analy-
sis had a health care sector perspective with the inclusion of costs
of hormone stimulation, visits, ultrasound, IVF, ICSI and inpa-
tient stay at the hospital. Danish unit costs (2005) were applied.
Differences in costs were compared with differences in effects to
